Literature DB >> 15908413

Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses.

Paulo Henrique da Costa Pinheiro1, Suzana de Souza Dias, Kelsen Dantas Eulálio, Ivete L Mendonça, Simone Katz, Clara Lúcia Barbiéri.   

Abstract

High in vitro lymphoproliferative responses were induced in humans and dogs by a recombinant Leishmania (Leishmania) chagasi cysteine proteinase, with secretion of IFN-gamma in asymptomatic subjects or of IFN-gamma, interleukin 4 (IL-4), and IL-10 in oligosymptomatic subjects. In contrast, responses of symptomatic patients and dogs were lower, with production of IL-4 and IL-10.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15908413      PMCID： PMC1111849          DOI： 10.1128/IAI.73.6.3787-3789.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  16 in total

1.  Inducible nitric oxide synthase and nitric oxide production in Leishmania infantum-infected human macrophages stimulated with interferon-gamma and bacterial lipopolysaccharide.

Authors:  M A Panaro; A Acquafredda; S Lisi; D D Lofrumento; T Trotta; R Satalino; M Saccia; V Mitolo; O Brandonisio
Journal:  Int J Clin Lab Res       Date:  1999

2.  Immunological features of kala-azar.

Authors:  H R Rezai; S M Ardehali; G Amirhakimi; A Kharazmi
Journal:  Am J Trop Med Hyg       Date:  1978-11       Impact factor: 2.345

3.  A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis.

Authors:  Suzana de Souza Dias; Paulo Henrique da Costa Pinheiro; Simone Katz; Márcia Regina Machado dos Santos; Clara Lúcia Barbiéri
Journal:  Am J Trop Med Hyg       Date:  2005-02       Impact factor: 2.345

4.  Serum cytokine profile in the subclinical form of visceral leishmaniasis.

Authors:  M E A Gama; J M L Costa; J C R Pereira; C M C Gomes; C E P Corbett
Journal:  Braz J Med Biol Res       Date:  2003-12-18       Impact factor: 2.590

5.  Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection.

Authors:  E M Carvalho; R S Teixeira; W D Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

6.  Gamma interferon production by lymphocytes from children infected with L. chagasi.

Authors:  O Bacellar; M Barral-Netto; R Badaró; E M Carvalho
Journal:  Braz J Med Biol Res       Date:  1991       Impact factor: 2.590

7.  Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis.

Authors:  Sima Rafati; Alireza Nakhaee; Tahere Taheri; Andishe Ghashghaii; Ali Hatef Salmanian; Maribel Jimenez; Mehdi Mohebali; Slavica Masina; Nicolas Fasel
Journal:  Exp Parasitol       Date:  2003 Mar-Apr       Impact factor: 2.011

8.  Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi.

Authors:  E M Carvalho; A Barral; D Pedral-Sampaio; M Barral-Netto; R Badaró; H Rocha; W D Johnson
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

9.  Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population.

Authors:  Alireza Nakhaee; Tahere Taheri; Mohammad Taghikhani; Mehdi Mohebali; Ali-Hatef Salmanian; Nicolas Fasel; Sima Rafati
Journal:  Vet Parasitol       Date:  2004-01-30       Impact factor: 2.738

10.  Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster.

Authors:  C L Barbiéri; A I Doine; E Freymuller
Journal:  Exp Parasitol       Date:  1990-08       Impact factor: 2.011
View more
  10 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs.

Authors:  A E Bivona; L Czentner; A Sanchez Alberti; N Cerny; A C Cardoso Landaburu; C Nevot; O Estévez; J D Marco; M A Basombrio; E L Malchiodi; S I Cazorla
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

3.  A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.

Authors:  Fabiana Rodrigues de Santana; Danielle Aparecida Marino da Silva; Simone Katz; Cristina Mary Orikaza; Katia Cristina Oliveira; Clara Lúcia Barbiéri
Journal:  Parasitol Res       Date:  2022-08-23       Impact factor: 2.383

4.  Proteinases as virulence factors in Leishmania spp. infection in mammals.

Authors:  Mariana Silva-Almeida; Bernardo Acácio Santini Pereira; Michelle Lopes Ribeiro-Guimarães; Carlos Roberto Alves
Journal:  Parasit Vectors       Date:  2012-08-07       Impact factor: 3.876

5.  Studies on the CPA cysteine peptidase in the Leishmania infantum genome strain JPCM5.

Authors:  Hubert Denise; Jacqueline Poot; Maribel Jiménez; Audrey Ambit; Daland C Herrmann; Arno N Vermeulen; Graham H Coombs; Jeremy C Mottram
Journal:  BMC Mol Biol       Date:  2006-11-13       Impact factor: 2.946

Review 6.  Animal models for the study of leishmaniasis immunology.

Authors:  Elsy Nalleli Loría-Cervera; Fernando José Andrade-Narváez
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jan-Feb       Impact factor: 1.846

Review 7.  Humoral and Cellular Immune Response in Asymptomatic Dogs with Visceral Leishmaniasis: A Review.

Authors:  Ana García-Castro; Adriana Egui; María Carmen Thomas; Manuel Carlos López
Journal:  Vaccines (Basel)       Date:  2022-06-14

8.  A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Authors:  Connor Carson; Maria Antoniou; Maria Begoña Ruiz-Argüello; Antonio Alcami; Vasiliki Christodoulou; Ippokratis Messaritakis; Jenefer M Blackwell; Orin Courtenay
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

9.  Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Authors:  Josie Haydée Lima Ferreira; Lucilene Dos Santos Silva; Ieda Maria Longo-Maugéri; Simone Katz; Clara Lúcia Barbiéri
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

10.  Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule.

Authors:  Danielle A M da Silva; Fabiana R Santana; Simone Katz; Daniel M Garcia; Daniela Teixeira; Ieda M Longo-Maugéri; Clara L Barbiéri
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.